Barinthus Biotherapeutics’ (BRNS) “Buy” Rating Reiterated at HC Wainwright

Barinthus Biotherapeutics (NASDAQ:BRNS)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $5.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 497.34% from the company’s previous close.

Separately, Alliance Global Partners cut their price objective on Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating on the stock in a research report on Tuesday, August 13th.

Barinthus Biotherapeutics Stock Performance

Shares of BRNS stock opened at $0.84 on Tuesday. The firm has a market cap of $33.10 million, a P/E ratio of -0.56 and a beta of -0.59. Barinthus Biotherapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $4.16. The business’s 50 day moving average price is $1.28 and its 200-day moving average price is $1.51.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.23. The business had revenue of $14.97 million during the quarter. During the same quarter in the prior year, the company posted ($0.37) EPS. As a group, equities analysts predict that Barinthus Biotherapeutics will post -1.52 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Catalina Capital Group LLC purchased a new position in shares of Barinthus Biotherapeutics in the 2nd quarter valued at approximately $25,000. Ipswich Investment Management Co. Inc. purchased a new position in Barinthus Biotherapeutics during the second quarter valued at $32,000. BlueCrest Capital Management Ltd purchased a new position in Barinthus Biotherapeutics during the first quarter valued at $1,292,000. DC Funds LP purchased a new position in Barinthus Biotherapeutics during the first quarter valued at $1,528,000. Finally, Alphabet Inc. purchased a new position in Barinthus Biotherapeutics during the second quarter valued at $2,119,000. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.